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Ductal carcinoma in situ (DCIS) is a precursor lesion
of invasive ductal carcinoma (IDC) of the breast. To
understand the dynamics of genomic alterations in
this progression, we used four multicolor fluores-
cence in situ hybridization probe panels consisting
of the oncogenes COX2, MYC, HER2, CCND1, and
ZNF217 and the tumor suppressor genesDBC2, CDH1,
and TP53 to visualize copy number changes in 13
cases of synchronous DCIS and IDC based on single-
cell analyses. The DCIS had a lower degree of chro-
mosomal instability than the IDC. Despite enormous
intercellular heterogeneity in DCIS and IDC, we ob-
served signal patterns consistent with a nonrandom
distribution of genomic imbalances. CDH1 was most
commonly lost, and gain ofMYC emerged during pro-
gression from DCIS to IDC. Four of 13 DCISs showed
identical clonal imbalances in the IDCs. Six cases re-
vealed a switch, and in four of those, the IDC had
acquired a gain of MYC. In one case, the major clonein the IDC was one of several clones in the DCIS, and
in another case, the major clone in the DCIS became
one of the two major clones in the IDC. Despite con-
siderable chromosomal instability, in most cases the
evolution from DCIS to IDC is determined by recur-
rent patterns of genomic imbalances, consistent with
a biological continuum. (Am J Pathol 2012, 181:
1807–1822; http://dx.doi.org/10.1016/j.ajpath.2012.07.012)
Ductal carcinoma in situ (DCIS) is considered a precursor
lesion for invasive breast cancer, and it is found synchro-
nously in 45% of patients with invasive ductal carci-
noma (IDC).1 DCIS is the last step in a continuum of
noninvasive stages of increased cellular atypia that are
believed to develop from flat epithelial atypia and atypical
ductal hyperplasia.2 During the past decades, the ob-
served incidence of DCIS has increased dramatically,
which is likely attributable to more frequent screening
and improved imaging methods.3 DCIS and IDC occur
with an estimated incidence of 35 and 155 per 100,000
women in the United States, respectively.4 As the name
suggests, the defining difference between these two entities
is the lack of invasion and the maintenance of basement
membrane integrity in DCIS. This particular feature has a
profound effect on the prognosis for the patient. Patients
with DCIS not accompanied by invasive disease have a
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AJP November 2012, Vol. 181, No. 55-year survival of nearly 100%, but that rate drops with the
diagnosis of IDC, which varies depending on tumor stage.5
The crucial clinical difference between DCIS and IDC
has prompted considerable research activity aimed at
identifying the relationship between the two. Histomor-
phologic and epidemiologic studies showed similarities
between these lesions.6 Furthermore, genetic and molec-
ular cytogenetic approaches, namely, studies of loss of
heterozygosity, mutation analyses, gene expression pro-
filing, comparative genomic hybridization (CGH), fluores-
cence in situ hybridization (FISH), and other assays for
determining genomic copy number changes, supported
the interpretation that DCIS is a precursor of IDC.7–23
However, the precise sequence of genetic events that
causes the progression is not known. Most studies que-
ried aberration profiles in the tumor cell population as a
whole. The analysis of average changes in the entire
tumor population makes it more difficult to ask the follow-
ing two-part question: Does linear clonal evolution exist
during transition from preinvasive to invasive disease,
and, if so, which patterns of genomic imbalances drive
this process? To address this issue, we used interphase
cytogenetics on intact nuclei of the DCIS and the IDC
component of primary tumor samples with probe cock-
tails targeting genes frequently affected by copy number
changes in this disease. In particular, the genes that were
included are described in the following paragraphs.
COX2 (cyclooxygenase 2, located on 1q31.1) is up-
regulated in human breast cancer and encodes a key
enzyme in the production of prostaglandins, which stim-
ulate cell proliferation, inhibit apoptosis, and promote
metastasis and angiogenesis in mammary tumor cells.24
DBC2 (deleted in breast cancer, located on 8p21.3), also
known as RhoBTB2, belongs to the RhoBTB subfamily of
Rho GTPases and inhibits cellular proliferation.25 This
activity is proposed to occur through an uncharacterized
mechanism wherein RhoBTB2 down-regulates the ex-
pression of cyclin D1.26 MYC (c-MYC, located on
8q24.21) is a regulator gene coding for a transcription
Table 1. Clinical Data Available for the 13 Patients Analyzed
Case No. Age (years) Race Tumor g
1 50.0 Hispanic 3
2 47.3 White 1
3 73.9 White 3
4 53.0 White 1
5 62.7 White 2
6 33.3 White 2
7 56.0 White 3
8 59.7 White 2
9* 66.1 African American 2
10 42.8 Hispanic 3
11 49.6 Asian 3
12 37.0 White 2
13 37.8 White 3
*Case 9 was the only case with distant metastasis.
ER, estrogen receptor (0 is a positive test result); G/P/AB, gravida/p
receptor (0 is a positive test result).factor that can activate and modify the expression ofnumerous genes, thereby driving cell proliferation and
regulating cell growth, apoptosis, differentiation, and
stem cell self-renewal. MYC is a strong proto-oncogene
and is up-regulated in many types of cancers.27 CCND1
(cyclin D1, located on 11q13.3) is the regulatory subunit
of a holoenzyme that phosphorylates and inactivates the
RB protein and promotes progression through the G1-S
phase of the cell cycle in a manner dependent on
CDKs.28 Amplification or overexpression of CCND1 plays
a pivotal role in the development of several human can-
cers, breast cancer included.
CDH1 (cadherin1, also known as epithelial cadherin,
located on 16q22.1) encodes a calcium ion–dependent
cell adhesion molecule whose reduced expression is re-
garded as one of the main molecular events involved in
dysfunction of the cell-cell adhesion system, triggering
cancer invasion and metastasis.29 HER2 (human epider-
mal growth factor receptor 2, located on17q12), also
known as NEU or ERBB2, encodes a tyrosine kinase
receptor that mediates critical signaling functions.30 Am-
plification or overexpression of the HER2 gene occurs in
approximately 30% of breast cancers and is strongly
associated with increased disease recurrence and worse
prognosis.31 TP53 (tumor protein p53, located on
17p13.1) is a short-lived transcription factor that plays a
critical role in eliminating tumor cells by coordinating
changes in gene expression, leading to cell cycle arrest,
senescence, or apoptosis.32,33 TP53 has, therefore, been
described as the “guardian of the genome.”34 TP53 ac-
tivity is frequently lost in human cancers.35
ZNF217 (zinc finger protein 217, located on 20q13.2)
emerged as a strong candidate oncogene in the region of
amplification on chromosome 20q13.2 for breast and
other cancers. It is a member of the C2H2 family of
transcription factors and is believed to intervene in the
processes of transcriptional repression and attenuation
of the apoptotic signal.36
By analyzing these eight gene probes along with two
centromeric control probes (centromeres 4 and 10) in the
Tumor size (cm)
Lymph nodes















rtus; IHC, immunohistochemical; ND, not determined; PR, progesteroneradesame cells using subsequent hybridization and relocation
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dynamics that govern the evolution of breast cancer.
Materials and Methods
Clinical Samples
The samples were collected from women enrolled be-
tween 2000 and 2006 in an ongoing, Institutional Review
Board–approved, hospital-based epidemiologic study
assessing biomarkers of breast cancer risk. Clinical data
were collected at the time of participant entry with no
longitudinal follow-up. Included were English-speaking
women 18 years of age who had a previous diagnosis
of IDC or DCIS at any age or no history of any form of
cancer, excluding nonmelanoma skin cancers and in situ
cervical cancer. The study nurse identified patients with
synchronous DCIS and IDC from the database of enrolled
women, and the representative paraffin blocks were se-
lected. The clinical data available for the 13 patients
analyzed are summarized in Table 1. Owing to updates to
the consensus staging criteria for breast cancer that oc-
curred during the enrollment period, the staging provided
in Table 1 is based on the current American Joint Com-
mittee on Cancer cancer staging system.37
Preparation of Cytospins from Archival
Formalin-Fixed, Paraffin-Embedded Specimens
Nuclei from archived paraffin blocks were prepared us-
ing the cutting scheme presented in Figure 1, A. First, a
4-m-thick section was cut and stained with H&E and the
histomorphologic features of each lesion were assessed by
a pathologist (R.C.). The second and third sections were
6-m-thick (for potential FISH or immunohistochemical
studies on tissue sections), and the fourth and fifth sections
were 50 m thick. The sixth section was 4-m-thick and








0 0 1 G4
75 85 ND G3
75 100 ND G2
90 100 1 G1
100 95 2 G5
90 40 1 G4
0 0 0 G0
5 95 0 G4
100 50 2 G2
0 0 0 G3
90 80 3 G2
0 0 3 G2
95 90 2 Misstaining for the DCIS and the IDC for case 5 as an example.Using the two H&E-stained sections for guidance, the
pathologist (R.C.) outlined the DCIS and IDC areas in the
unstained 50-m-thick sections. The tissue of each area
of interest was removed using a scalpel and was placed
in an Eppendorf tube with xylene for 20 minutes. The tube
was then centrifuged for 3 minutes at 750  g, and the
xylene was removed. The xylene wash was repeated an
additional two times. The tissue was then rehydrated in
















Figure 1. A: Sample preparation for FISH analysis. First, a 4-m-thick sec-
tion was cut and stained with H&E for the identification of regions containing
DCIS and IDC. The second and third sections were 6 m thick (for potential
FISH or immunohistochemical studies), and the fourth and fifth sections were
50 m thick and were used for the preparation of nuclei for FISH analysis.
The sixth section was 4 m thick and was also stained with H&E. After macro-













singslides as cytospin preparations and fixed for FISH analysis. B: Examples of
H&E-stained sections of DCIS and IDC, shown here from case 5.
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minutes at 16,000  g. The ethanol was removed, and 1
mL of sterile water was added. After 20 minutes at room
temperature, the sample was centrifuged at 4°C for 15
minutes at 16,000  g. After removing the water, 250 to
500 L of 0.1% protease (type XXIV; P-8038; Sigma-
Aldrich, St. Louis, MO) in 1 PBS was added. The tube
was then placed in an Eppendorf thermomixer at 45°C,
shaking for 40 to 60 minutes.
The disintegration of the tissue sample was monitored
under microscopic control every 15 to 20 minutes. The
degree of disintegration was determined by placing 10
L of the protease digest on a slide and staining it with 10
L of DAPI-sulforhodamine solution (SR101; S-7635;
Sigma-Aldrich). Optimal disintegration was determined
by the quantity of nuclei (30 per 16 objective field
view) and by the lack of cytoplasm and the intensity of the
DAPI stain. Once the disintegration was optimal, the re-
action was stopped with 500 L of 1 PBS, and the
sample was centrifuged for 5 minutes at 530  g. The
concentration of the nuclei was adjusted so that 80 L of
the cell suspension centrifuged in a Shandon Cytospin 3
centrifuge (Thermo Scientific, Asheville, NC) for 5 min-
utes at 180  g resulted in a medium-dense, monolay-
ered cytospin. The slides were dehydrated in 70% and
90% ethanol for 5 minutes and in 100% ethanol for 10
minutes, air-dried, and stored at 4°C.
FISH
Eight bacterial artificial chromosome contigs centering
around the following genes were assembled: COX2
(1q31.1), DBC2 (8p21.3), MYC (8q24.21), CCND1
(11q13.3), CDH1 (16q22.1), HER2 (17q12), TP53
(17p13.1), and ZNF217 (20q13.2). The bacterial artificial
chromosome clones for COX2, CCND1, CDH1, and TP53
were labeled with Orange-dUTP (Abbott Molecular Inc.,
Des Plaines, IL), and those for MYC, DBC2, HER2, and
ZNF217 were labeled in green with DY-505-dUTP (Dyo-
mics, Jena, Germany). Two centromere probes (CEP4 and
CEP10) labeled with Aqua-dUTP (Abbott Molecular Inc.)
were hybridized in addition to the eight gene probes.
The FISH probes were combined into four panels, with
CCND1 and ZNF217 as the first panel. The second panel
contained MYC, COX2, and CEP10. HER2, TP53, and
CEP4 were in the third panel. The fourth panel contained
DBC2 and CDH1. The four probe panels were consecu-
tively hybridized onto the same cytospin, allowing for
counts of all 10 probes in the same nuclei. Before hybrid-
izations, the samples were pretreated with 0.05% pepsin
(P-6887; Sigma-Aldrich). The slides were then dehy-
drated in an ethanol series (70%, 90%, and 100%) for 5
minutes each and allowed to air-dry. The slides were
denatured in 70% formamide/standard saline citrate for 2
minutes at 80°C using a ThermoBrite StatSpin system
(Abbott Molecular Inc.) and were dehydrated in a cold
ethanol series (70%, 90%, and 100%) for 3 minutes each
and allowed to air-dry. The probes were denatured for 5
minutes and preannealed for 1 to 2 hours before being
hybridized onto the samples. Coverslips were then
added and sealed with rubber cement. The slides wereplaced into a humid hybridization chamber and incu-
bated at 37°C overnight.
After hybridization, slides were washed twice in 2
standard saline citrate at room temperature for 2 minutes
with gentle agitation. The slides were then dehydrated (in
70%, 90%, and 100% ethanol for 2 minutes each), air-
dried, and covered with Vectashield mounting medium
containing a DAPI counterstain (Vector Laboratories, Bur-
lingame, CA) before the slides were analyzed using a
Leica DMRXA epifluorescence microscope with an auto-
mated stage (Leica Microsystems GmbH, Wetzlar, Ger-
many) equipped with custom optical filters for DAPI,
Spectrum Aqua, Spectrum Green, and Spectrum Orange
(Chroma Technology Corp., Bellows Falls, VT) with a 40
plan apochromat (numerical aperture, 1.25) objective.
The microscope was connected to a CoolSNAPfx CCD
camera (Roper Scientific GmbH, Ottobrunn, Germany).
Leica CW4000 FISH software (Leica Microsystems) was
used to acquire 25 to 30 images with each filter. Stage
relocation was used so that the same cells could be
imaged with all four probe panels. Once the samples had
been imaged with the first panel, the first probe panel
was washed off in 50% formamide/standard saline citrate
at 80°C for 1 to 2 minutes and then dehydrated in an
ethanol series (70%, 90%, and 100% for 2 minutes each).
Once dry, the slides were denatured in 70% formamide/
standard saline citrate for 2 minutes at 80°C using the
ThermoBrite StatSpin and dehydrated in a cold ethanol
series (70%, 90%, and 100% for 3 minutes each). The
denatured and preannealed probes containing the gene
probes were then mixed with the denatured centromere
probes and hybridized overnight at 37°C. The probe sig-
nals were developed according to the protocol used for the
first probe panel, and images were taken for the same cells
as imaged in the first panel using the relocation software.
The previously described protocol was then repeated for
the third and fourth panels. All the samples were analyzed
for the eight gene probes and the two centromere probes,
with a final count of 76 to 220 interphase nuclei for each
sample. Only nuclei with clearly visible signals for all four
subsequently hybridized probe panels were included in the
final count. The nuclei were checked after each hybridiza-
tion and were excluded if damaged or incomplete. This was
easily assessed by comparison with images of the previous
hybridizations. The counts for each cell and each probe
were then recorded in Excel spreadsheets (Microsoft Corp,
Redmond, WA; Table 2).
Raw Patient Data Files
We recorded the results of the enumeration as raw data
for DCIS and IDC separately per patient and saved those
as tab-delimited text files for the various analyses de-
scribed later herein. Table 2 is an example of the raw
data for the IDC of case 1, which shows 20 of 59 rows of
the raw data file. The first 10 columns are the signal
counts of two centromere probes (CEP10 and CEP4) and
eight gene probes (COX2, DBC2, MYC, CCND1, CDH1,
TP53, HER2, and ZNF217). The rows were sorted in lex-
icographic ascending order. The eight genes are in chro-
mosome order. Each row of 10 probe signal counts is called
n the ta
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tern were grouped into one row. The second to last right
column reports the number of distinct nuclei having the
signal pattern described by that row. Nuclei with signal
patterns that have a high likelihood of resulting from trunca-
tion artifacts were filtered out as described later herein.
Preprocessing Patient Data Files
The DCIS and the IDC lesions showed varying contribu-
tions of cells with diploid counts for all markers, presum-
ably from stromal or immune cells. Cells with a count of
two signals for all probes were eliminated from the sub-
sequent data analysis.
In addition, we used two methods to filter out signal
patterns that are likely contributed by sectioned nuclei.
The first method is based on counting oncogene probe
signals based on the intuition that oncogenes should
rarely be lost and that nuclei with subdiploid signals from
oncogenes are, therefore, likely to be cut. Probabilities of
signal counts expressed as percentages of signal counts
for all centromere and gene probes across all cells are
reported in Table 3. For each signal pattern, we multiplied
the probabilities of the observed signal counts for the five
Table 2. Examples of Signal Patterns and Ploidy Annotation for
CEP10 CEP4 COX2 DBC2 MYC CCND1
1 2 2 2 2 2
1 2 2 2 2 2
1 2 2 2 2 2
– – – – – –
2 2 2 2 2 2
2 2 2 2 2 2
– – – – – –
4 2 3 2 4 2
4 2 3 2 4 2
4 2 3 2 4 3
4 2 3 3 4 1
4 2 3 3 4 2
4 2 3 3 4 2
4 2 3 3 4 2
4 2 3 3 4 2
4 2 3 3 4 2
4 2 3 3 4 2
4 2 3 3 4 3
4 2 3 3 4 3
4 2 3 4 4 2
4 2 3 4 4 2
4 2 4 4 4 2
– – – – – –
Frequent signal patterns are shown in bold. Dashes indicate places i
Table 3. Probabilities Expressed as Percentages of Signal Counts
Data Files (of DCIS and IDC Separated for 13 Patients)
Signal
count CEP10 CEP4 COX2 DBC2
0 0.57 0.85 0.63 3.08
1 4.49 4.25 3.35 29.35
2 94.94 94.91 96.02 67.56 9The probabilities for oncogene probes are shown in bold.oncogenes to obtain a likelihood of the observed count
under the null hypothesis of no cut nucleus. To make the
test more cautious, we heuristically multiplied this likeli-
hood by 10 for each oncogene probe with three or more
counts. We identified any nucleus with adjusted likeli-
hood 0.0004 as a probably cut nucleus and filtered it
from the data set. This threshold was chosen because
there was a large gap between the highest value below
0.0004 and the lowest value above.
The second method of filtering relied on the premise
that complete loss of any chromosome was likely an
indication of a cut nucleus. We, therefore, filtered any cell
in which either centromere probe (CEP10 or CEP4) has
zero signals, which occurred with percentages of 0.57%
for CEP10 and 0.85% for CEP4 (Table 3). A total of 104
cells across all data files were filtered out as being likely
to reflect sectioned, incomplete nuclei.
Annotating Ploidy
To infer probe signals being gained or lost, we assigned
an overall ploidy to each signal pattern. We then classi-
fied probe gain or loss relative to the estimated overall
ploidy of the cell. Cells were predominantly classified as
of Case 1





1 2 2 1 2
2 2 0 1 2
2 2 2 3 2
– – – – –
2 2 2 1 2
2 2 2 4 2
– – – – –
2 2 1 1 2
2 2 2 5 2
2 2 2 1 2
2 1 2 1 2
1 2 1 1 2
1 2 2 2 2
2 2 2 11 2
3 4 2 1 2
2 2 2 1 2
2 3 2 1 2
2 2 2 1 2
2 4 2 1 2
2 2 2 1 2
2 2 2 3 2
2 3 2 1 2
– – – – –
ble where rows of the Excel file are omitted.
o Centromere Probes and Eight Gene Probes from 26 Patient
CCND1 CDH1 TP53 HER2 ZNF217
1.87 2.40 1.42 0.92 1.24
4.30 34.68 22.98 10.46 3.87
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4). Only a few cells were assigned a ploidy 4. Ploidy
values were assigned to each signal pattern by expert
(K.H.-H.) annotation based on an assessment of centro-
mere counts and gene probe counts for that pattern to
generate ploidy assignments consistent with centromere
counts when those were in agreement, using gene
counts and knowledge of which genes were oncogenes
versus tumor suppressors to reconcile disagreements in
centromere counts. Table 2 provides some examples of
signal patterns from the IDC of case 1 and their assigned
ploidies. We additionally developed a computational
maximum likelihood model for ploidy assignment, trained
based on a subset of manual assignments. To infer ploidy
computationally, we computed the conditional probability
of each probe count (grouped into 0, 1, 2, 3, and 4) for
each manually assigned ploidy (2, 3, or 4) across all cells
and probes and assigned a weight to each probe to
estimate its contribution to the overall ploidy assignment
(weight 1 for COX2, CCND1, CDH1, and ZNF217; weight
0.5 for DBC2, MYC, TP53, and HER2; weight 0 for any
centromere probe with signal count 1; weight 2 for any
centromere probe with signal count 2 where both cen-
tromere probes were present; and weight 3 for a centro-
mere probe with signal count 2 where it was the only
centromere probe available). To assign a ploidy to a
given cell, we then computed a probability of each ploidy
assignment (2, 3, or 4) by computing the weighted sum
over all probes of the conditional probability of the ob-
served signal count given the putative ploidy, normalizing
the resulting probabilities by the sum of all three for each
cell. We then treated the most probable of these three
assignments as the computationally assigned ploidy of
the cell provided that its probability was above an empir-
ically determined threshold of 0.63. If the most probable
assignment was 2, that assignment had a probability
between 0.63 and 0.55, and at least three probes had
signal count 5, then we instead assigned the ploidy to
be the more probable of ploidies 3 and 4. Similarly, if the
most probable assignment was 2, that assignment had a
probability 0.55, and at least four gene probes had
signal count 5, then we assigned the ploidy to be the
more probable of ploidies 3 and 4. The computational
method was used to assist in manual ploidy assignment
by checking that similar cells in different patient files were
assigned the same ploidy.
Determining Gain and Loss Patterns
Because of the large number of probes and the high
diversity in clonal populations, there tend to be small
numbers of any particular signal pattern in any particular
lesion. To better characterize the major progression
steps of individual patients, we, therefore, developed a
procedure to identify a subset of probes specific to each
patient that best describes the major clonal evolution of
that patient. By identifying only those probes relevant to
the common progression steps found in a given patient
and the directions of the corresponding count changes,
we can consolidate distinct signal patterns common to agiven pathway and, thus, identify the strongly supported
pathways.
To classify progression patterns consistently across
patients, we used the notion of a signal pattern compar-
ator, which describes a possible direction of change for
each probe in a given patient.38 A comparator consists of
a string using four symbols— gained (G), normal (N), lost
(L), and a wild card symbol () indicating a probe that is
not considered—with one symbol assigned for each
probe from the ordered set COX2, DBC2, MYC, CCND1,
CDH1, TP53, HER2, and ZNF217. For example, a tumor
that is characterized by gain of HER2 and loss of TP53 in
a background of normal MYC would be described by the
comparator NLG. Such a comparator then serves
as a summary for all signal patterns exhibiting normal
MYC, loss of TP53, and gain of HER2 regardless of their
counts for the other probes. There are 48 possible com-
parators for the eight-probe data used herein. We fo-
cused this analysis on the 381 comparators consisting
of G, L, and  but not all .
We analyzed the frequency with which each compar-
ator was satisfied in each patient data set. To do so, we
assigned each signal pattern a string of the symbols G,
N, and L describing its counts of the eight probes relative
to its ploidy. For example, in the major signal pattern
clone of the IDC of case 1 (Table 2, fourth row with bold
numbers), relative to the ploidy assignment of 2, we ob-
serve gains of COX2, DBC2, and MYC and a loss of
CDH1.We, therefore, would assign that signal pattern the
string GGGNLNNN. This was repeated for all signal pat-
terns. We then asked for each patient data set what
fraction of cells satisfied each of the 48 possible compar-
ators. A cell satisfies a comparator if the cell’s signal
pattern agrees with the comparator in all non–wild card
characters. For example, the signal pattern GGGNLNNN
would match comparators GGGNLNNN, GGGLNNN,
GGGL, GGG, , etc. For each data set,
we identified comparators containing only G, L, and 
and matching 20% of that patient’s cells. Comparators
with no N’s matching30% of the cells in a data set were
defined as major imbalance clonal patterns, and those
matching 20% but 30% were defined as minor imbal-
ance clonal patterns. If we did not find any major imbal-
ance clonal pattern matched by 30% of the cells in a
patient file, we instead identified the one most frequent
imbalance clonal pattern even if its frequency was30%.
Results
DCIS is the noninvasive precursor lesion of IDC. To ex-
plore the dynamics and the sequence of genome altera-
tions that determine the progression from DCIS to syn-
chronous IDC, we used 10 FISH probes to enumerate
chromosomal copy number changes in single cells. This
was accomplished by sequential hybridization of four
FISH cocktails that contained the probes for the onco-
genes COX2 (1q), MYC (8q), CCND1 (11q), HER2 (17q),
and ZNF217 (20q); the tumor suppressor genes DBC2
(8p), CDH1 (16q), and TP53 (17p); and centromere enu-
meration probes for chromosomes 4 and 10. Chromo-
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ploidy of the cells because these chromosomes are
rarely subject to copy number changes in breast can-
cer.39 The probes were sequentially hybridized to inter-
phase cells prepared as cytospins from 13 cases of
synchronous DCIS and IDC from the same patients. Sig-
nal patterns were counted in 76 to 220 nuclei per sample.
This procedure allowed us to establish the copy numbers
of the same 10 probes in each interphase nucleus. The
clinical samples were collected with informed consent as
part of an Institutional Review Board–approved hospital-
based observational study to assess biomarkers of
breast cancer risk. Pertinent clinical parameters are sum-
marized in Table 1.
Maintenance of Conserved Patterns of Genomic
Imbalances
In general, we observed that the pattern of chromosomal
gains and losses is consistent with previous cytogenetic,
molecular cytogenetic (CGH), and genetic studies, which
indicated that the distribution of chromosomal gains and
losses defines the cancer entity.40,41 The selection of the
probes was based on published data on numerical ab-
errations in breast cancer.39 Accordingly, the breast can-
cer–specific FISH markers delineating chromosome arms
1q, 8q, 11q, 17q, and 20q were frequently present in
extra copy numbers, whereas 8p, 16q, and 17p were
subject to copy number losses in DCIS and IDC in the
present collection (Figure 2). Gains of COX2 and MYC
Figure 2. Average gain and loss frequencies for all the gene markers in cells
of DCIS and IDC. Percentages of cells with gains are shown above the 0% line
and with losses below the 0% line.and losses of DBC2, CDH1, and TP53 occurred in 30%of all cells, and gains of CCND1, HER2, and ZNF217 were
observed in 20% of all cells. Chromosome arms that
were frequently gained were rarely lost, and vice versa,
except 17q (HER2), which was gained in 25% of cells
but lost in 10% of DCIS and IDC. The HER2 loss ob-
served was attributable to two cases (cases 6 and 10).
The frequency of chromosomal gains and losses was, in
general, higher in the cells of IDC compared with those of
DCIS, which was particularly obvious for the MYC onco-
gene (15% more IDC cells with MYC gain compared with
DCIS cells). Only the gains of COX2 and CCND1 were
slightly (2%, not statistically significant) higher in DCIS
cells (Figure 2).
Figure 3 shows the number of DCIS and IDC lesions
positive for a specific marker gain or loss when using a
threshold of30% of the cells of the lesion displaying the
aberration. For all copy number changes, except CCND1
gain, which remained at identical levels (5 of 13 cases
each), the number of samples with that change increased
during the progression from DCIS to IDC. For most mark-
ers, an increase of one or two lesions was observed;
however, theMYC gain was much more prominent in IDC
lesions, with an increase from 6 of 13 DCIS lesions to 10
of 13 IDC lesions. MYC gains and CDH1 losses (11 of 13
IDC lesions) were the most frequent changes found in the
IDC lesions analyzed in this study.
To arrive at a quantitative assessment of the degree of
genomic instability, we calculated an instability index by
dividing the number of distinct observed signal patterns
by the numbers of enumerated nuclei and then multiply-
ing by 100 to put the instability index values in the range
[0,100]. DCIS had an average chromosomal instability of
62.3 (range, 14.5–93.3), and the synchronous IDC re-
vealed an average instability of 70.6 (range, 49.7–98.0),
summarized in Table 4.
Three of the 13 samples (cases 1, 2, and 4) displayed
a pattern that would be consistent with the 1q/16q pattern
identified using array CGH and gene expression profil-
ing, which defines a particular subgroup of invasive can-
 
No. of lesions with >30% of cells 
with specific marker gain or loss 
Marker DCIS IDC 
COX2 gain 8 9 
DBC2 loss 7 8 
MYC gain  6 10 
9 11 
CCND1 gain  5 5 
CDH1 loss  
TP53 loss  4 6 
HER2 gain  3 4 
3 5 
HER2 loss 2 1 
ZNF217 gain  
Figure 3. Specific gene gains and losses during progression from DCIS to
IDC. Note that HER2 was gained and lost. The thicknesses of the arrows
reflect the percentage of change from DCIS to IDC. The increase of lesions
with a gain of MYC was the most pronounced.
IS and t
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somal gains and losses and the instability index, which
correlated with each other, with clinical parameters, we
noticed the following relationships: DCISs that preceded
grade 1 IDCs were more stable than DCISs that pre-
ceded grades 2 and 3 IDCs (P  0.0128, Mann-Whitney/
Wilcoxon test). IDCs with more imbalances and a higher
instability index were preceded by DCISs that were also
more unstable. Furthermore, the degree of instability in-
creased with tumor grade, and, last, high-grade DCIS
lesions were more likely to progress to grade 3 tumors. In
addition, we observed a good correlation when compar-
ing HER2 overexpression measured by immunohisto-
chemical analysis (Table 1) with genomic gain or ampli-
fication of HER2 determined using FISH.
Chromosomal Instability and Clonal Patterns
The FISH probe panels were hybridized sequentially to
individual nuclei. After repeated hybridization and relo-
cation of the cells, this afforded us the possibility of enu-
merating clonal aberration patterns on a cell-to-cell basis
for all eight gene probes and the two centromere probes.
We then assigned the FISH signal patterns to two groups:
patterns for which each cell fitting the pattern has an
identical count as each other cell fitting the pattern for all
eight gene signals, termed signal pattern clone, and pat-
terns for which each cell fitting the pattern matches each
other cell in the direction of change (gain, loss, or normal)
Table 4. Stable Signal Pattern Clones and Instability Indexes for
Case No. Lesions Sta
1‡ DCIS 16% 3342122
IDC 13% 3342122
2‡ DCIS 21% 2222122
IDC 14% 3222122
3‡ DCIS 6% 42982244
IDC 6% 42982244
4‡ DCIS 18% 4222122
IDC 10% 4332122
5 DCIS 22% 3123113
IDC 11% 4233213




8‡ DCIS 12% 2142122
IDC 9% 21421222
9‡ DCIS 7% 72442246
IDC 8% 72442246








*Signal patterns are displayed in the following gene order: COX2, DBC
†Average instability of DCIS vs IDC: 62.3 vs 70.6. The instability inde
nuclei counted.
‡Cases with identical signal pattern clones (shown in bold) in the DC
§Lesions with no stable signal pattern clones: 4% of cells have idenof each signal but not necessarily in the exacts counts,termed imbalance clone. To visualize and compare major
imbalance clones in synchronous DCIS and IDC lesions,
we displayed each cell of the lesion according to its gain,
loss, or unchanged (normal) status, with the gene probes
sorted according to their chromosomal location from the
top to the bottom of the chart and with the patterns
observed displayed from left to right sorted by frequency.
In addition, we calculated the frequency of gained and
lost, status for each of the gene loci in percentages of the
total DCIS or IDC cell population, the average ploidy of
the lesion, and the average signal number for each gene
locus. The results are displayed in Figure 4 for the first six
cases and in Supplemental Figure S1 (available at http://
ajp.amjpathol.org), for the remaining seven cases.
The enormous degree of chromosomal instability
was reflected by the fact that identical signal pattern
clones were present only in 23% of the cells of each
lesion and in seven lesions in 4% of the cells, which
we defined as lesions without a stable signal pattern
clone (Table 4). However, imbalance clones were de-
tected invariably, but not in all cases was a major
imbalance clone that was present in the DCIS also
maintained in the matched IDC.
Table 5 summarizes the major imbalance clones in each
lesion determined with the help of the gain and loss com-
parator described inMaterials andMethods. All major imbal-
ance clone patterns match30% of the cells in a patient file
except for the DCIS lesions of cases 2, 10, 12, and 13 and
the IDC lesion of case 3. The imbalance clone with the
IS and IDC Lesions of 13 Patients
nal pattern clones* Instability index†
32421222 61.1
32421222 67.4




32221222, 6% 42221122 43.7
42221222, 7% 43321122 63.4


















, CCND1, CDH1, TP53, HER2, ZNF217.




















x is calclargest corresponding percentage in DCIS is also the one
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of four patients (cases 1, 7, 8, and 9). For example, the
imbalance clone (DBC2 lost, MYC gained, CDH1 lost)
matching comparator LGL with the highest percent-
age (32.6%) in the DCIS of case 8 was also the imbalance
clone with the highest percentage (40.7%) in the IDC of that
case. We infer that cells with this imbalance clone had a
growth advantage in both the DCIS and IDC lesions.
Clonal Evolution
In general, we discerned four categories of different pro-
gression patterns from DCIS to IDC, which are described
in detail in the following paragraphs.
Category I included four cases in which the major
imbalance clone in the DCIS was also dominant in the
IDC. Supplemental Figure S1G (available at http://ajp.
amjpathol.org), shows that the most frequent imbalance
clone in the DCIS and the IDC of case 7 had gains of
COX2, MYC, CCND1, and ZNF217 and a loss of DBC2,
whereas CDH1, TP53, and HER2 were unchanged. In the
second most frequent imbalance clone, additional losses
of CDH1 and TP53 were observed for both lesions,
whereas HER2 was gained in the DCIS and lost in the IDC
clone. The signal patterns suggested isochromosome
formation 8q for most of the DCIS and IDC cells and
isochromosome 17q for a subset of the DCIS cells; how-
ever, a stable signal pattern clone was not present (Table
4). Case 9 (see Supplemental Figure S1I at http://ajp.
amjpathol.org) revealed a pattern consistent with isochro-
mosomes 8q and 17q. All oncogenes were gained and all
tumor suppressor genes were lost, and we observed
major, identical imbalance clones. Case 1 (Figure 4A)
revealed gains of COX2, DBC2, and MYC and a loss of
CDH1 and a major signal pattern clone in 16% and 13%
of DCIS and IDC, respectively (pattern 33421222 in Table
4). It also had a minor signal pattern clone with a
32421222 pattern (5% and 6%, respectively; Table 4).
The latter pattern would be consistent with the acquisition
of isochromosome 8q, whereas the major pattern could
be explained by a gain of two chromosomes 8, one of
which lost DBC2. Finally, case 8 (see Supplemental Fig-
ure S1H at http://ajp.amjpathol.org) was dominated by
losses of DBC2 and CDH1 and a gain of MYC, again
consistent with isochromosome 8q, and contained iden-
tical signal clones (Table 4).
Category II included one case (case 2 in Figure 4B) in
which one of several major imbalance clones in the DCIS
later dominated the IDC. This clone displayed a gain of
COX2 and a loss of CDH1. The second most frequent
clone in the IDC displayed a 32221122 pattern (Table 4)
corresponding to a TP53 loss in addition to the COX2
gain and CDH1 loss. This signal pattern clone was not
detected in the DCIS, indicating that the TP53 loss was a
late event. The frequent DCIS clone with gains of COX2
and ZNF217 was not carried over to the IDC. This partic-
ular DCIS was the most stable case (instability index,
14.5) and revealed three signal pattern clones that ac-
counted for 50% of all the nuclei. The IDC showed
markedly more instability (instability index, 49.7; Table 4).Category III contained case 3 (Figure 4C), for which
the dominant clone in the DCIS, which was defined by
losses of DBC2, CDH1, and TP53 and gains of MYC and
CCND1, was found among two major clones in the IDC.
The second IDC clone exhibited a COX2 gain as the only
change. Consequently, the percentages of MYC and
CCND1 gains and DBC2, CDH1, and TP53 losses were
substantially lower in the IDC than in the DCIS.
Finally, category IV comprised six cases in which we
observed a switch of a major clone between the DCIS
and the IDC. In four of these cases, the progression from
DCIS to IDC was defined by the acquisition of extra
copies of the MYC oncogene. In case 10 (see Supple-
mental Figure S1J at http://ajp.amjpathol.org), the major
clone in the IDC showed losses of DBC2, CDH1, and the
entire chromosome 17 and a gain of MYC not present in
the DCIS. In case 4 (Figure 4D), the 1q/16q pattern that
defined the DCIS was replaced by a clone that in addition
to the COX2 gain and CDH1 loss showed gains of DBC2
(8p) and MYC (8q) that would be indicative of the gain of
the entire chromosome 8, whereas in case 12 (see Sup-
plemental Figure S1L at http://ajp.amjpathol.org), gains of
MYC, HER2, and ZNF217 emerged after the transition to
IDC. The dominant DCIS clone exhibiting a sole loss of
CCND1 was not present in the IDC. In case 5 (Figure
4E), three frequent signal pattern clones were detected
in the DCIS (22% 31231132, 16% 31221132, and 7%
31241132; Table 4), which resulted in a major imbalance
clone defined by gains of COX2, CCND1, and HER2 and
losses of DBC2, CDH1, and TP53. In contrast, the major
imbalance clone in the IDC displayed an additional MYC
gain, whereas DBC2 and CDH1 were not lost. This clone
was represented by the following new signal pattern
clones: 42332132 (11%) and 42342132 (6%), as shown
in Table 4. The signal numbers for TP53 and HER2 were
consistent with isochromosome 17q and identical be-
tween the DCIS and IDC clones, which might indicate a
common origin for the evolution of these clones. The
DCIS contained two cells with the exact signal pattern of
the major cancer clone and one cell with the second most
common cancer clone pattern. On the other hand, 13
cells (7%) in the IDC exhibited the major signal patterns
of the DCIS. In case 11 (see Supplemental Figure S1K at
http://ajp.amjpathol.org), losses of CDH1 and TP53 oc-
curred only in the IDC, which also had acquired extra
copies of HER2, whereas the DBC2 loss and MYC ampli-
fication were already present in the DCIS. The signal
count for MYC was more stable in the IDC. In case 6
(Figure 4F), a prominent gain of COX2 was not main-
tained in the associated IDC; however, the DBC2 loss
and an unusual HER2 loss persisted.
In one case (case 13; see Supplemental Figure S1M at
http://ajp.amjpathol.org), it was difficult to determine a dom-
inant clone because no stable signal clone evolved. With
most signal counts fluctuating between two and four signals
and with only COX2 and ZNF217 being more consistently in
the four-signal range, this case seems to be quite different
from the others. However, the IDC and DCIS cells, although
the latter in a smaller fraction, showed the same kind of
instability and tendency for higher copy numbers for COX2
and ZNF217, suggesting a relationship.
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AJP November 2012, Vol. 181, No. 5Figure 4. Summary of imbalance clones in 6 of the 13 cases of DCIS and IDC (cases 1 to 6; A–F). Green, gains; red, losses; blue, unchanged. The organization
of the graphs is the same for all cases and is explained for A (case 1) in detail from left to right. The “Locus” column shows the chromosome arm. Each vertical
dotted line separates individual nuclei, and the vertical thin solid line discerns specific signal pattern clones among the most common imbalance clones, which
are separated from each other by vertical thick solid lines. The row above the imbalance clones displays the percentages at which the clones were found (threshold
2%). For example, the DCIS of case 1 had 20% of cells with gains of COX2, DBC2, and MYC and a loss of CDH1, and the other markers were unchanged; among
those cells, 15.8% had a signal pattern clone of 33421222 in the DCIS. In the IDC, 16.3% of cells had gains of COX2, DBC2, and MYC and a loss of CDH1, with
no other changes observed; among those, 12.8% had a signal pattern clone of 33421222 (for the definitions of imbalance clone and signal pattern clone, see
Materials and Methods). There were 8.4% of the cells with gains of COX2 and MYC and a loss of CDH1 as the only changes, and in this imbalance clone there
were five cells with a signal pattern clone of 32421222. The “Marker” column shows the gene name. The “Gain” column shows that 51% of the cells had a gain
of COX2, 36% of DBC2, and 60% of MYC in the DCIS. The “Loss” column shows that 55% of the cells had a loss of CDH1 in the DCIS. The “sig. no.” column shows
that the average signal count for COX2 in the entire population was 2.53 (2.35 for DBC2, 3.06 for MYC, and 1.49 for CDH1). The percentage of gains or losses
in 30% of the cells is also indicated by the color intensity. Ninety-five nuclei were counted for the DCIS of this case, and 86 for the IDC. Average ploidy values
were calculated from the ploidy values assigned to each nucleus (see Materials and Methods). Columns that are presented in blue only had no copy number
changes for any of the eight gene probes but signal numbers for centromere probes 4 and/or 10 that differed from the ploidy value. The remaining seven cases
(cases 7 to 13) can be viewed in Supplemental Figure S1 (available at http://ajp.amjpathol.org).
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DCIS to IDC, which are presented in Figure 5, with repre-
sentative examples for each of the four categories.
Conclusions
The aberration patterns of DCIS suggest that these le-
Figure 4. (continued)sions are well advanced in the progression to an invasivecarcinoma because in most cases the targeted loci were
already gained or lost and the instability index was high.
From a mechanistic point of view, the observed patterns
point to isochromosome formation for 8q and, to a lesser
extent, 17q. Gains of COX2 and MYC, together with
losses of DBC2, CDH1, and TP53, occurred most fre-
quently. The relationship between DCIS and IDC was
also investigated by developing rule-based models,
e comp
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certain gains and losses were correlated with each other,
and neither was it such that certain gains and losses
precluded the necessity to acquire additional changes.
However, two of the three cases without aMYC gain in the
major IDC clone presented with imbalance clones de-
fined by only two gene changes on a diploid background;
one case was consistent with the already mentioned 1q/
16q pathway, and one case displayed an unusual HER2
loss combined with a DBC2 loss. The latter tumor was
found in a young woman (33 years old) and presented
with a size of 4.5 cm. The remaining case without a MYC
gain was case 13, for which we could not establish a
clear major clone pattern. The gain of MYC, in terms of
cells in each of the tumors with a gain of this oncogene
and in terms of cases of IDC, seems to be a marker for
progression from localized to invasive disease.
Discussion
In 45% of breast carcinomas, the invasive lesion,
IDC, is accompanied by a synchronous, noninvasive
DCIS.1 A considerable body of literature suggests that
there are similarities in terms of the aberration patterns be-
Table 5. Major and Minor Clonal Patterns Separately in DCIS an
Corresponding Percentages Matched by Cells in Each P
Case No. DCIS IDC
1 GGL (40.0%) GGL (41.9%)
GGG (33.7%) GGG (40.7%)
GGL (31.6%) GGL (31.4%)
GGGL (29.5%) GGGL (27.9%)
2 GL (28.6%) GL (45.1%)
GG (28.6%) LL (22.3%)
LL (21.4%)




4 GL (66.2%) GGGL (35.7%)
GLL (21.4%)






6 GLL (35.1%) LL (37.9%)
7 GLGGG (52.8%) GLGGG (48.9%)
GLGGL (33.7%) LL (34.4%)
GLGLG (30.7%) GGL (30.0%)
LG (30.7%) GL (30.0%)
GLGGL (30.1%) LGL (30.0%)
GLGLL (30.1%) GLGGLG (23.3%)
GLGGLL (26.4%) LLL (23.3%)
GLGGLG (20.9%) GLGGLG (21.1%)
GLGGG (22.1%) GLLL (20.0%)
GLGGLG (21.5%) GGLL (20.0%)
GLGLLG (21.5%) GL (20.0%)
GLGGG (21.5%) LLG (20.0%)
LGGG (20.9%) LL (20.0%)
GGGG (20.2%)
GGGG (20.2%)
Major clonal patterns are shown in bold. The order of the probes in thtween these lesions (reviewed by Sgroi2). This evidenceis based on gene expression analyses,12–14,18,20,21
CGH,8–11,16,17,19,20 FISH,15,43–45 and molecular inversion
probe arrays,46 which analyze DNA or RNA extracted
from bulk tumor samples.
Herein, we used single-cell genetic analysis based
on interphase cytogenetics to understand genome dy-
namics during progression. This allowed us to dissect
pathways of carcinogenesis and to identify patterns of
genomic imbalances and clonal evolution. We used
four FISH probe panels that target eight chromosomal
arms frequently subject to copy number changes in
breast cancer (plus two centromere probes). The se-
quential hybridization of these panels to nuclei pre-
pared from synchronous DCIS and IDC enabled us to
enumerate all probe counts in single, individual cells to
determine nonrandom chromosomal gains and losses,
to assess the degree of intratumor heterogeneity, and
to reconstruct clonal relationships between these le-
sions.
We observed an astonishingly high degree of chromo-
somal instability from one cell to another, which was
reflected in the fact that identical signal clones were
present in 20% of the cells, except for three samples
(Figure 4 and Table 4; see also Supplemental Figure S1
or Each Patient as Matching Comparators with Their
ile in Parentheses for all 13 Patients
se No. DCIS IDC
8 LGL (32.6%) LGL (40.7%)
LL (21.3%)
9 GLGGLLGG (32.6%) GLGGLLGG (42.3%)
10 LL (19.7%) LGLLL (46.6%)
11 GLG (37.3%) LGLL (34.3%)
GGG (31.4%) GGG (31.3%)
GLGG (22.5%) GGG (31.3%)
GLGG (20.6%) GGLG (30.3%)


























arator string is COX2, DBC2, MYC, CCND1, CDH1, TP53, HER2, ZNF217.d IDC f
atient F
Caat http://ajp.amjpathol.org). Despite this instability, in most
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with the genomic aberration profile described previously
for breast cancer,47,48 specifically, the relative gains of
chromosome arms 1q, 8q, 11q, 17q, and 20q, accompa-
nied by losses of chromosome arms 8p, 16q, and 17p.
This was also reflected by the aberration patterns of the
four cases subsumed in category I. In these cases, it
seemed likely that the DCIS and the IDC are related since
the same major imbalance clone(s) was found in the
DCIS and the adjacent IDC. All these cases showed a
prominent gain of MYC and a loss of CDH1, frequently
also accompanied by a gain of COX2 and a loss of DBC2.
We interpreted this finding to indicate, in accordance with
the results shown in Figure 4 and Supplemental Figure S1
(available at http://ajp.amjpathol.org), that copy number
changes of these loci, once acquired in DCIS, continue to
be strongly selected for during the progression to inva-
sive disease. It also means that alterations to an estab-
lished breast cancer–specific imbalance pattern were not
likely to change during progression to an invasive phe-
notype. A pictorial presentation of clonal progression pat-
terns in two cases in category I is presented in Figure 5,
A and B.
An obvious degree of relatedness was also observed
in categories II and III. In category II, which is repre-
sented by case 2, only one of three major clones in DCIS
(gain of COX2 and loss of CDH1) was dominant in the IDC
(Figure 4B). The most frequently observed clone in the
DCIS (gains of COX2 and ZNF217) was not present in the
IDC, and the clone defined by the sole loss of CDH1 in
the DCIS was significantly less abundant in the IDC. We
interpret this finding to indicate that the loss of cell ad-
hesion alone, as reflected by a copy number loss of
CDH1, is not sufficiently competitive during progression.
However, the sole gain of two oncogenes in the absence
of loss of CDH1 also does not prevail, but rather the
combination of CDH1 loss and COX2 gain. The emer-
gence of a frequent clone with the additional loss of TP53
after transition to IDC suggests that this loss is a late
event (Figure 5C). In case 3, in category III, a clearly
dominant clone in DCIS (gains of MYC and CCND1 and
losses of DBC2, CDH1, and TP53) was one of two clones
in IDC, albeit considerably less frequent (Figure 4C). The
second most common clone, characterized by the sole
gain of COX2, was present in only three cells in the DCIS.
Despite the relatedness of the most common clone, this
observation would indicate a parallel evolution during
disease progression. Also, a clone with a single aber-
ration would compete against one with imbalances in
five of eight genes associated with breast tumorigenesis
(Figure 5D).
In 6 of 13 cases (category IV), the imbalance clones
shifted during the progression from DCIS to IDC, which
triggered the interpretation that even if genomic gains
and losses that favor tumor progression were acquired in
DCIS, they were not necessarily maintained in the
matched IDC. For example, in case 6, the clone defining
the IDC (losses of DBC2 and HER2) was present in only
two cells in the DCIS. The major clone in DCIS, which
contained in addition to losses of DBC2 and HER2 a gain
of COX2, did not prevail in the IDC (Figure 5E). In four ofthe six cases in category IV, the clonal switch from DCIS
to IDC was associated with the gain of MYC in 50% of
the cells. This gain could occur either as a gain of the
entire chromosome 8 (case 4) or as an isochromosome
8q (case 12; see Supplemental Figure S1L at http://ajp.
amjpathol.org). Case 5 (Figure 4E) serves as an example
of a MYC gain during progression. None of the major
clones in the DCIS that did not carry a gain of MYC were
still present in substantial numbers in the IDC, yet the
major IDC clone was defined by gains ofMYC even in the
absence of losses of two tumor suppressor genes (DBC2
and CDH1), although these losses were part of the major
DCIS clone. Thus, it seems that extra copies of MYC are
important for the acquisition of an invasive phenotype
(Figure 5F).
In two cases, the shift of the major clone did not de-
pend on the acquisition of a MYC gain in the IDC. Case 6
Figure 5. Schematic presentation of examples of clonal evolution in
categories I (A and B), II (C), III (D), and IV (E and F) based on the
presence of imbalance clones. These graphs were derived from the results
summarized in Figure 4 and in Supplemental Figure S1 (available at
http://ajp.amjpathol.org). For example, in case 8 (A), the major clone in
DCIS [an 18.8% gain of MYC (8q), losses of DBC2 (8p) and CDH1
(16q)] was also the major clone in IDC (13.3%). A rare clone in the DCIS
(a gain of MYC, losses of DBC2, CDH1, and ZNF217) expanded to
become the second largest clone, whereas the second largest clone in
DCIS (a gain of MYC, a loss of CDH1) became rare in the IDC. The text on
the left of each panel denotes whether specific chromosome arms are
gained () or lost (). The sizes of the circles reflect the frequency with
which a clone occurred, which is specified by the percentages in the
circles as well. In C, the clone that occurred in 7.4% in the IDC could have
emerged by losses of 17p from either the major clone in the DCIS (1q,
16q) or the IDC clone present in 13.7% of the cells. Note that one of the
major clones in the DCIS (1q, 20q) vanished in the IDC.has already been discussed. In the other case (case 11;
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the amplification of MYC and the loss of DBC2 that were
already present in the DCIS were maintained in the IDC;
however, new aberrations, such as CDH1 loss, TP53 loss,
and HER2 gain, consistent with an isochromosome 17q
formation, emerged as additional changes.
Intuitively, the relatedness of DCIS and IDC with re-
spect to disease progression would be reflected in a
pattern in which clones that emerged in the preinvasive
lesion prevailed in the IDC. This pattern would be con-
sistent with the hypothesis that the cells in a precursor
lesion such as DCIS are continuously evolving, resulting
in clonal expansion of the most successful combination of
traits. Such an evolutionary progression, in which each
intermediate step of gains and losses would be repre-
sented in the sample, was not always observed. This gap
might indicate that the pressure that forces the selection
of a certain imbalance clone can change during progres-
sion, eg, from a primarily growth-promoting incentive in
the DCIS to an environment in which invasiveness and
perhaps avoidance of programmed cell death become
more important. The gain of MYC, or the expansion of
clones that carry MYC gains, seems to play a major role
in this transition in the present samples; this is consistent
with the prominent role that MYC plays as a regulator of
epithelial/mesenchymal transition, invasion, and metas-
tasis.27
The fact that despite the high degree of genomic in-
stability in most instances, imbalance patterns consistent
with those observed in the IDC were already present in
the DCIS indicates that DCIS and IDC are genetically
related lesions, not unlike preinvasive precursor lesions
in cervical and colorectal tumorigenesis.49–51 However,
the DCIS lesions are, according to their aberration pat-
terns, far further advanced than, eg, colorectal polyps or
cervical dysplasias, in which the genome remains more
stable, and gains and losses of single chromosomes,
often in a diploid genome, are more common.50,51 Chro-
mosomal instability, defined herein as a variability in the
signal patterns from one cell to another in a tumor cell
population, is predominant in DCIS and IDC; hence, both
can be considered late events in breast tumorigenesis.
The considerable degree of intercellular heterogeneity
in the DCIS convincingly attests to the fact that chro-
mosomal instability precedes the transition to invasive
disease. This result would be consistent with the inter-
pretation that chromosomal instability per se is a nec-
essary condition for the acquisition of an imbalance
spectrum that is required for cancer progression and
invasiveness. This nimbleness of cancer cells, re-
flected by the considerable instability index, might al-
low adaptation to environmental stressors that are as-
sociated with hypoxia, the process of invasion and
metastasis, and treatment interventions, all of which
are challenges that a carcinoma as a novel species
has to overcome when evolving from local to advanced
and disseminated disease.52–54
The high degree of aneuploidy and chromosomal in-
stability further corroborate the central role of these ge-
nome mutations in cancer and support the interpretation
that genomic instability alone can serve as a potent bio-marker for progression risk and clinical outcome.55–57 In
a previous FISH study of breast carcinomas, we showed
that this degree of genomic instability and intratumor
heterogeneity, as determined by quantitative measure-
ment of the DNA content and by FISH, determined out-
come.58 Aubele et al59,60 demonstrated elegantly the
important role of intratumoral heterogeneity in breast le-
sions using laser-capture microdissection and CGH on
ductal hyperplasia, DCIS, and invasive carcinomas. Re-
cently, Gerlinger et al61 revealed considerable fluctuation
in the mutation spectrum in individual tumors by applying
exome sequence analysis, chromosome aberration anal-
ysis, and ploidy profiling to multiple microdissected re-
gions of renal cell carcinomas and their metastases. This
heterogeneity was attributable to a distinct clonal muta-
tion spectrum and to aneuploidy. Arguably, measuring
potentially relevant biomarkers for a bulk tumor sample
would underestimate the degree of clonal variability. This
is supported by the present findings.
From a clinical point of view, the high degree of chro-
mosomal instability and the advanced aberration profile
of DCIS make it unlikely that progression to invasive dis-
ease can be prevented with measures other than surgery
and radiation. It is difficult to imagine that the enormous
number of genomic imbalances and the sheer number of
independent clones could be reversed by interventions
that would be accepted in the realm of cancer preven-
tion, not cancer therapy. It also seems reasonable to
infer that among the many independent imbalance
composition clones, some that are equipped with an
aberration pattern required for metastases already ex-
ist in the DCIS.52,62
For patients with cancer, the transition from locally
controlled disease to a disseminated stage and metas-
tases is perhaps the most critical threshold because that
transition makes surgical intervention with curative intent
considerably less likely to succeed. We could now show
that preinvasive DCIS, which is associated with excellent
5-year survival rates, is defined by chromosomal aberra-
tion patterns and degrees of genomic instability similar to
invasive disease. This, of course, raises the following
question: What precisely determines this critical transition
between preinvasive and invasive disease? It is now es-
tablished that chromosomal imbalances directly affect
the transcription of genes that reside on chromosomes
or chromosomal regions affected by copy number
changes.63 The enormous amount of chromosomal gains
and losses in DCIS and IDC, therefore, results in a mas-
sive deregulation of the cancer transcriptome, which is a
direct reflection of the distribution of genomic imbal-
ances. Consequently, the idiosyncrasies of aneuploidy-
dependent transcriptional changes of individual tumors
might hamper attempts to dissect gene expression pro-
files that distinguish the noninvasive from the invasive
and metastatic phenotype. We submit that careful cata-
loguing of differences in the transcriptome of DCIS and
IDC, in particular in cases in which a major aberrant clone
is present in both entities, such as in the cases compiled
in category I, could have the potential of identifying a
gene expression signature that is ultimately responsible
for invasion and disease progression.
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